Consensus on the management of patients with diabetes mellitus and cardiovascular disease
DOI:
https://doi.org/10.47196/diab.v55i1Sup.466Keywords:
guidelines, diabetes mellitus, cardiovascular diseases, epidemiology, risk factors, prevention, cardiovascular risk assessment, patient management, pharmacological treatment, revascularization, heart failureAbstract
This Consensus comes to light in the midst of one of the worst global health crises in the last 100 years. SARS-CoV-2 and its clinical manifestation, COVID-19, have caused a disruption in how doctors and patients interact. Although it is an infectious disease, one of the most notable characteristics is that its mortality increases in patients with chronic non-communicable diseases and, in particular, with a history of diabetes and cardiovascular disease.
In this context, then, we believe that the recommendations made in this document, which aim to identify and protect these patients, become more relevant, while the implementation, beyond the statements, of specific cardiometabolic prevention policies becomes a priority.
References
Norgaard ML, Andersen SS, Schramm TK, et al. Changes in short and long-term cardiovascular risk of incident diabetes
and incident myocardial infarction. A nation wide study. Diabetologia 2010; 53(8):1612-1619. DOI:10.1007/s00125-010-1783-z.
Mulnier HE, Seaman HE, Raleigh VS, et al. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 2008; 51(9):1639-1645. DOI:10.1007/s00125-008-1076-y.
Eliasson B, Cederholm J, Eeg-Olofsson K, et al. Clinical usefulness of different lipid measures for prediction of coronary
heart disease in type 2 diabetes: a report from the Swedish National Diabetes Register. Diabetes Care 2011; 34(9):2095-2100.
DOI:10.2337/dc11-0209.
Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:
United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ 1998; 316:823-828.
Vergès B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31(5):429-439.
Vergès B. Lipid disorders in type 1 diabetes. Diabetes Metab 2009; 35(5):353-360. DOI:10.1016/j.diabet.2009.04.004.
Doucet J, Le Floch J-P, Bauduceau B, Verny C; SFD/SFGG Intergroup. GERODIAB: Glycaemic control and 5-year morbidity/
mortality of type 2 diabetic patients aged 70 years and older: 1. Description of the population at inclusion. Diabetes Metab
; 38(6):523-530. DOI:10.1016/j.diabet.2012.07.001.
Margeirsdottir HD, Larsen JR, Brunborg C, Overby NC, Dahl-Jørgensen K; Norwegian Study Group for Childhood Diabetes. High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 2008; 51(4):554-561. DOI:10.1007/s00125-007-0921-8.
Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. Insulin acutely inhibits intestinal lipoprotein secretion in humans in
part by suppressing plasma free fatty acids. Diabetes 2010; 59(3):580-587. DOI:10.2337/db09-1297.
Malmström R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40(4):454-462. DOI:10.1007/s001250050700.
Nogueira JP, Maraninchi M, Béliard S, et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 2012; 32(4):1039-1044.
DOI:10.1161/ATVBAHA.111.242073.
Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, Steinberg D. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 1982; 31(4 Pt 1):283-291. DOI:10.2337/diab.31.4.283.
Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003; 26(5):1540-1544. DOI:10.2337/diacare.26.5.1540.
Goff DC, D’Agostino RB, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metab Clin Exp 2005; 54(2):264-270. DOI:10.1016/j.
metabol.2004.09.002.
Chan DC, Barret PHR, Watts GF. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional
studies employing stable isotopy and modelling methods. Clinical Science 2004; 107(3):233-249.
Verges B, Brun JM, Vaillant G, et al. Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and
on its relationship with prevalence of atherosclerosis in type 2 diabetes. Diabetes Metab 1992; 18(4):289-297.
Brites FD, Cavallero E, de Geitere C, Nicolaïew N, Jacotot B, Rosseneu M, Fruchart JC, Wikinski RL, Castro GR. Abnormal
capacity to induce cholesterol efflux and a new LpA-I pre-beta particle in type 2 diabetic patients. Clin Chim Acta 1999; 279(1-2):1-14.
Castillo-Núñez Y, Aguilar-Salinas CA, Mendivil-Anaya CO, Rodríguez M, Lyra R. Consenso del Grupo de Tareas de la Asociación Latinoamericana de Diabetes (ALAD) sobre el diagnóstico y manejo de la dislipidemia diabética. Rev ALAD 2018; 8:118-40.
Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M. Fasting is not routinely required for determination of a lipid lrofile: clinical and laboratory implications including flagging at desirable concentration cutpoints. A joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2016; 62(7):930-46.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
